



November 16, 2015

The Corporate Relationship Department
BSE Limited
Floor 25, P J Towers, Dalal Street,
Mumbai – 400 001.

The Manager – Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra –Kurla Complex
Bandra (E)
Mumbai – 400 051

Dear Sirs/ Madam,

Sub: Press release

Please find enclosed the press release in connection with the USFDA ANDA approval.

Thanking You,

Yours faithfully,

For Shasun Pharmaceuticals Limited


S. Hariharan,

Chief Financial Officer



SCGA/F-001/K/14

Shasun Pharmaceuticals Limited

"Batra Centre"

No. 28, Sardar Patel Road, Post Box 2630, Guindy, Chennai-600 032, India.

Phone: 91-44-4344 6700 / 2220 7500, Fax: 91-44-2235 0278

email : shasun@shasun.com Website : www.shasun.com

TIN No. 33191540153, CST No.39072 / 06.09.76

CIN : L24117TN1976PLC007122

PRESS RELEASE

Shasun Pharmaceuticals receives USFDA approval for Carisoprodol Tablets

Product to be launched shortly

Chennai, November 16, 2015: Shasun Pharmaceuticals Limited (BSE: 524552, NSE: SHASUNPHAR) today announced that it has received approval from the United States Food & Drug Administration (USFDA) for **Carisoprodol Tablets USP 250 mg and 350 mg**.

Carisoprodol Tablets 250 mg & 350 mg has sales of approximately USD 38 million. While the 350 mg has few Generic players, Shasun expects to be the first marketed generic player in the USD 16 Million Carisoprodol Tablets 250 mg opportunity.

The product will be manufactured at the Pondicherry facility of the Company and distributed in US through a partner. The product is expected to be launched shortly.

About Carisoprodol Tablets

Carisoprodol is a muscle relaxer that works by blocking pain sensations between the nerves and the brain. Carisoprodol is used together with rest and physical therapy to treat injuries and other painful musculoskeletal conditions.

About Shasun Pharmaceuticals Limited:

Shasun Pharmaceuticals Ltd, listed on the Bombay Stock Exchange Limited (stock code: 524552) and the National Stock Exchange of India Limited (stock code: SHASUNPHAR) is an integrated pharmaceutical company with its head office in Chennai, India and offices in UK and USA.

For further information please contact:

Shasun Pharmaceutical Limited

Mr. S. Hariharan,
Chief Financial Officer

hari@shasun.com

+91 98410 46299

www.shasun.com



Safe Harbor

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Shasun Pharmaceuticals Limited may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

